Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress
Heron Therapeutics (NASDAQ:HRTX) reported strong Q2 2025 financial results with total net revenue of $37.2 million, a 3.3% increase year-over-year. The company's Acute Care franchise showed impressive growth of 55.5% year-over-year in Q2 2025.
Key highlights include ZYNRELEF unit demand growth of 6.3% and APONVIE unit demand growth of 19% in Q2 compared to Q1 2025. The company completed a capital restructuring, reducing total debt from $175M to $145M and extending maturities to 2030.
Heron raised its 2025 Adjusted EBITDA guidance to $9.0-$13.0 million from $4.0-$12.0 million, while reaffirming net revenue guidance of $153-$163 million. The company ended Q2 with $40.6 million in cash and equivalents.
Heron Therapeutics (NASDAQ:HRTX) ha riportato solidi risultati finanziari nel secondo trimestre del 2025 con un ricavo netto totale di 37,2 milioni di dollari, in aumento del 3,3% rispetto all'anno precedente. Il settore Acute Care dell'azienda ha mostrato una crescita impressionante del 55,5% anno su anno nel Q2 2025.
I punti chiave includono una crescita della domanda unitaria di ZYNRELEF del 6,3% e una crescita della domanda unitaria di APONVIE del 19% nel secondo trimestre rispetto al primo trimestre del 2025. L'azienda ha completato una ristrutturazione del capitale, riducendo il debito totale da 175 milioni a 145 milioni di dollari e prorogando le scadenze fino al 2030.
Heron ha aumentato la guidance per l'EBITDA rettificato 2025 a 9,0-13,0 milioni di dollari da 4,0-12,0 milioni, confermando al contempo la guidance sul ricavo netto tra 153 e 163 milioni di dollari. L'azienda ha chiuso il Q2 con 40,6 milioni di dollari in liquidità e equivalenti.
Heron Therapeutics (NASDAQ:HRTX) reportó sólidos resultados financieros en el segundo trimestre de 2025 con un ingreso neto total de 37,2 millones de dólares, un aumento del 3,3% interanual. La división de Atención Aguda de la compañía mostró un crecimiento impresionante del 55,5% interanual en el Q2 2025.
Los aspectos destacados incluyen un crecimiento de la demanda unitaria de ZYNRELEF del 6,3% y un crecimiento de la demanda unitaria de APONVIE del 19% en el segundo trimestre en comparación con el primer trimestre de 2025. La empresa completó una reestructuración de capital, reduciendo la deuda total de 175 millones a 145 millones y extendiendo los vencimientos hasta 2030.
Heron elevó su guía de EBITDA ajustado para 2025 a 9,0-13,0 millones de dólares desde 4,0-12,0 millones, mientras reafirmaba la guía de ingresos netos de 153-163 millones. La compañía terminó el Q2 con 40,6 millones de dólares en efectivo y equivalentes.
Heron Therapeutics (NASDAQ:HRTX)는 2025년 2분기에 총 순수익 3,720만 달러를 기록하며 전년 대비 3.3% 증가한 강력한 실적을 발표했습니다. 회사의 급성 치료 부문은 2025년 2분기에 전년 대비 55.5%라는 인상적인 성장을 보였습니다.
주요 내용으로는 2분기 ZYNRELEF 단위 수요가 1분기 대비 6.3% 증가했고, APONVIE 단위 수요는 19% 증가했습니다. 회사는 자본 구조 조정을 완료하여 총 부채를 1억 7,500만 달러에서 1억 4,500만 달러로 줄이고 만기를 2030년까지 연장했습니다.
Heron은 2025년 조정 EBITDA 가이던스를 기존 4.0-12.0백만 달러에서 9.0-13.0백만 달러로 상향 조정했으며, 순수익 가이던스는 1억 5,300만~1억 6,300만 달러로 재확인했습니다. 회사는 2분기 말에 4,060만 달러의 현금 및 현금성 자산을 보유하고 있습니다.
Heron Therapeutics (NASDAQ:HRTX) a annoncé de solides résultats financiers pour le deuxième trimestre 2025 avec un chiffre d'affaires net total de 37,2 millions de dollars, soit une augmentation de 3,3 % par rapport à l'année précédente. La division soins aigus de la société a affiché une croissance impressionnante de 55,5 % en glissement annuel au T2 2025.
Les points clés incluent une croissance de la demande unitaire de ZYNRELEF de 6,3 % et une croissance de la demande unitaire d’APONVIE de 19 % au deuxième trimestre par rapport au premier trimestre 2025. L’entreprise a finalisé une restructuration de son capital, réduisant sa dette totale de 175 millions à 145 millions de dollars et prolongeant les échéances jusqu’en 2030.
Heron a relevé ses prévisions d’EBITDA ajusté pour 2025 à 9,0-13,0 millions de dollars contre 4,0-12,0 millions, tout en confirmant ses prévisions de chiffre d’affaires net entre 153 et 163 millions de dollars. La société a clôturé le deuxième trimestre avec 40,6 millions de dollars en liquidités et équivalents.
Heron Therapeutics (NASDAQ:HRTX) meldete starke Finanzergebnisse für das zweite Quartal 2025 mit einem Gesamtnettoumsatz von 37,2 Millionen US-Dollar, was einem Anstieg von 3,3 % im Jahresvergleich entspricht. Das Acute Care-Geschäft der Firma verzeichnete im Q2 2025 ein beeindruckendes Wachstum von 55,5 % im Jahresvergleich.
Zu den wichtigsten Highlights zählen ein 6,3%iges Wachstum der ZYNRELEF-Einheitenachfrage und ein 19%iges Wachstum der APONVIE-Einheitenachfrage im zweiten Quartal im Vergleich zum ersten Quartal 2025. Das Unternehmen schloss eine Kapitalrestrukturierung ab, reduzierte die Gesamtschulden von 175 Mio. auf 145 Mio. US-Dollar und verlängerte die Fälligkeiten bis 2030.
Heron hob seine Prognose für das bereinigte EBITDA 2025 auf 9,0 bis 13,0 Millionen US-Dollar an, zuvor 4,0 bis 12,0 Millionen US-Dollar, und bestätigte die Netto-Umsatzprognose von 153 bis 163 Millionen US-Dollar. Das Unternehmen schloss das zweite Quartal mit 40,6 Millionen US-Dollar an liquiden Mitteln und Äquivalenten ab.
- Acute Care franchise revenue grew 55.5% year-over-year in Q2 2025
- APONVIE unit demand increased 19% in Q2 vs Q1 2025
- Raised full-year 2025 Adjusted EBITDA guidance to $9.0-$13.0 million
- Successful debt restructuring reduced total debt by $30 million
- CMS granted permanent J-code for ZYNRELEF effective October 2025
- Oncology revenue declined 9.0% year-over-year in Q2 2025
- SUSTOL revenue decreased 43.4% year-over-year in Q2 2025
- CINVANTI revenue dropped 3.1% year-over-year in Q2 2025
- ZYNRELEF revenue impacted by temporary wholesaler adjustment
Insights
Heron Therapeutics shows positive financial momentum with raised EBITDA guidance despite mixed Q2 product performance.
Heron Therapeutics delivered a $37.2 million revenue quarter, representing modest 3.3% year-over-year growth, while maintaining its full-year revenue guidance of $153-163 million. The company's most encouraging metric is its raised adjusted EBITDA guidance, now $9-13 million for 2025, up from the previous $4-12 million range, signaling improving operational efficiency.
The results reveal a tale of two business segments. The Acute Care franchise showed impressive 55.5% year-over-year growth in Q2, with APONVIE leading at 141.6% growth and ZYNRELEF contributing 40.4% growth. Meanwhile, the Oncology segment declined 9.0%, with SUSTOL dropping 43.4% and CINVANTI decreasing 3.1%. This pivot toward Acute Care appears strategic rather than concerning.
A particularly positive development is the comprehensive capital restructuring that reduced total debt from $175 million to $145 million while extending maturities to at least 2030. This significantly improves Heron's financial flexibility during its growth phase. With $40.6 million in cash and equivalents as of June 30, the company has reasonable runway to execute its commercial expansion plans.
For ZYNRELEF specifically, unit demand grew 6.3% quarter-over-quarter despite temporary wholesaler adjustments related to the VAN transition. The permanent, product-specific J-code from CMS effective October 1 should streamline reimbursement processes, potentially accelerating adoption in Q4. Similarly, APONVIE's 19% sequential unit growth demonstrates promising market penetration, now supported by a dedicated sales team targeting the 4 million surgical patients at risk for postoperative nausea and vomiting.
The company's organization of dedicated sales teams for both key products in Q3 represents a significant operational investment that should drive growth acceleration in the second half of 2025, though results may lag implementation by a quarter or two.
- Generated Q2 2025 Net Revenue of
$37.2 million $76.1 million $153 million $163 million - Delivered record year-to-date 2025 Adjusted EBITDA of
$7.9 million $4.0 million $12.0 million $9.0 million $13.0 million - ZYNRELEF® unit demand grew
6.3% in Q2 2025 as compared to Q1 2025, with revenue impacted by a temporary wholesaler adjustment from the 400mg VAN transition; momentum building ahead of expanded commercial initiatives and dedicated sales team in Q3 2025 - APONVIE® unit demand grew
19% in Q2 2025 as compared to Q1 2025, supported by increased adoption in hospital systems and momentum building ahead of the newly launched dedicated sales team in Q3 2025 - Completed comprehensive capital restructuring, reducing total debt from
$175 million $145 million
"As today's release demonstrates, we enter the third quarter with strong momentum and a clear focus on accelerating the expansion of our core products," said Craig Collard, Chief Executive Officer of Heron. "Our performance reflects the dedication of our team and the growing demand for innovative solutions that address critical patient needs. We remain committed to executing our strategic priorities, driving sustainable growth, and delivering long-term value to our stakeholders."
Financial Guidance for 2025
Item | 2025 Full-Year Guidance for Net Revenue and Adjusted EBITDA (in millions) | ||||
Original | Q1 Updated Guidance | Q2 Updated Guidance | |||
Net Revenue | |||||
Adjusted EBITDA | |||||
Business Highlights
- Heron's Acute Care franchise delivered revenue growth of
55.5% year-over-year in Q2 2025 and70.5% year-over-year for the first half of 2025, reflecting continued commercial execution and expanding adoption across the portfolio. - ZYNRELEF Updates:
- ZYNRELEF unit demand grew
6.3% in Q2 as compared to Q1 2025, as momentum builds ahead of expanded commercial pull-through initiatives planned for the second half of the year. - Commercial initiatives include launch of a reorganized, dedicated ZYNRELEF sales team in Q3 2025, and enhanced distributor incentives in select accounts – including both formulary and high potential non formulary accounts – to drive growth and accelerate adoption.
- Transition to the Vial Access Needle ("VAN") will be completed in Q3 2025, optimizing product preparation, handling and operating field sterility with ZYNRELEF in hospitals and ambulatory surgical centers across
U.S. - The Centers for Medicare and Medicaid Services ("CMS") has granted a permanent, product specific J-code for ZYNRELEF, effective October 1, 2025, streamlining reimbursement and improving billing clarity for both CMS and commercial payers in both hospital and ambulatory surgical center settings.
- ZYNRELEF unit demand grew
- APONVIE Updates:
- APONVIE unit demand increased
19% in Q2 as compared to Q1 2025, reflecting strong growth and setting the stage for further expansion. - As of July 1, a dedicated sales team is now focused exclusively on promoting APONVIE, leveraging recent access wins that collectively represent approximately 4 million of the approximately 35 million annual surgical patients at moderate to high risk for postoperative nausea and vomiting in the
U.S.
- APONVIE unit demand increased
- Cash, cash equivalents, and short-term investments were
$40.6
Net Revenue Performance - Three Months Ended June 30 (in thousands) | ||||
2025 | 2024 | Dollar Change | Percentage Change | |
Acute Care | 55.5 % | |||
APONVIE | 141.6 % | |||
ZYNRELEF | 40.4 % | |||
Oncology | (9.0 %) | |||
CINVANTI | (3.1 %) | |||
SUSTOL | (43.4 %) | |||
Total Net Revenue | 3.3 % | |||
Net Revenue Performance - Six Months Ended June 30 (in thousands) | ||||
2025 | 2024 | Dollar Change | Percentage Change | |
Acute Care | 70.5 % | |||
APONVIE | 226.7 % | |||
ZYNRELEF | 49.7 % | |||
Oncology | (5.6 %) | |||
CINVANTI | (1.3 %) | |||
SUSTOL | (33.0 %) | |||
Total Net Revenue | 7.7 % | |||
Conference Call and Webcast
Heron will host a conference call and live webcast on Friday, August 8, 2025, at 8:30 a.m. ET. The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron's website at www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron's website for sixty days following the call.
About ZYNRELEF® for Postoperative Pain
ZYNRELEF is the first and only extended-release dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of nonsteroidal anti-inflammatory drug meloxicam. ZYNRELEF is the first and only extended-release local anesthetic to demonstrate in Phase 3 studies significantly reduced pain and significantly increased proportion of patients requiring no opioids through the first 72 hours following surgery compared to bupivacaine solution, the current standard-of-care local anesthetic for postoperative pain control. ZYNRELEF was initially approved by the FDA in May 2021 for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty. In December 2021, the FDA approved an expansion of ZYNRELEF's indication to include foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures. On January 23, 2024, the FDA approved ZYNRELEF for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided. Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures.
Please see full prescribing information, including Boxed Warning, at www.ZYNRELEF.com.
About APONVIE® for Prevention of Postoperative Nausea and Vomiting ("PONV") Prevention
APONVIE is a substance P/neurokinin 1 (NK1) Receptor Antagonist (RA), indicated for the prevention of post operative nausea and vomiting (PONV) in adults. Delivered via a 30-second IV push, APONVIE 32 mg was demonstrated to be bioequivalent to oral aprepitant 40 mg with rapid achievement of therapeutic drug levels. APONVIE is the same formulation as Heron's approved drug product CINVANTI. APONVIE is supplied in a single-dose vial that delivers the full 32 mg dose for PONV. APONVIE was approved by the FDA in September 2022 and became commercially available in the
Please see full prescribing information at www.APONVIE.com.
About CINVANTI® for Chemotherapy Induced Nausea and Vomiting (CINV) Prevention
CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin as a single-dose regimen, delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen, and nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen. CINVANTI is an IV formulation of aprepitant, an NK1 RA. CINVANTI is the first IV formulation to directly deliver aprepitant, the active ingredient in EMEND® capsules. Aprepitant (including its prodrug, fosaprepitant) is a single-agent NK1 RA to significantly reduce nausea and vomiting in both the acute phase (0–24 hours after chemotherapy) and the delayed phase (24–120 hours after chemotherapy). The FDA-approved dosing administration included in the
Please see full prescribing information at www.CINVANTI.com.
About SUSTOL® for CINV Prevention
SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. SUSTOL is an extended-release, injectable 5-hydroxytryptamine type 3 RA that utilizes Heron's Biochronomer® drug delivery technology to maintain therapeutic levels of granisetron for ≥5 days. The SUSTOL global Phase 3 development program was comprised of two, large, guideline-based clinical studies that evaluated SUSTOL's efficacy and safety in more than 2,000 patients with cancer. SUSTOL's efficacy in preventing nausea and vomiting was evaluated in both the acute phase (0–24 hours after chemotherapy) and delayed phase (24–120 hours after chemotherapy).
Please see full prescribing information at www.SUSTOL.com.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.
Non-GAAP Financial Measures
To supplement our financial results presented on a GAAP basis, we have included information about certain non-GAAP financial measures. We believe the presentation of these non-GAAP financial measures, when viewed with our results under GAAP, provide analysts, investors, lenders, and other third parties with insights into how we evaluate normal operational activities, including our ability to generate cash from operations, on a comparable year-over-year basis and manage our budgeting and forecasting.
In our quarterly and annual reports, earnings press releases and conference calls, we may discuss the following financial measures that are not calculated in accordance with GAAP, to supplement our consolidated financial statements presented on a GAAP basis.
Adjusted EBITDA
Adjusted EBITDA is a non-GAAP financial measure that represents GAAP net income or loss adjusted to exclude interest expense, interest income, the benefit from or provision for income taxes, depreciation, amortization, stock-based compensation, and other adjustments to reflect changes that occur in our business but that we do not believe are indicative of ongoing operations. Adjusted EBITDA, as used by us, may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.
There are several limitations related to the use of adjusted EBITDA rather than net income or loss, which is the nearest GAAP equivalent, such as: adjusted EBITDA excludes depreciation and amortization and, although these are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA; we exclude stock-based compensation expense from adjusted EBITDA although: (i) it has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy; and (ii) if we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would be higher, which would affect our cash position; adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs; adjusted EBITDA does not reflect the benefit from or provision for income taxes or the cash requirements to pay taxes; and adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments.
Adjusted Operating Expenses
Adjusted operating expenses is a non-GAAP financial measure that represents GAAP operating expenses adjusted to exclude stock-based compensation expense, depreciation and amortization, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations. For more information on these non-GAAP financial measures, see the below table captioned "YTD Adjusted EBITDA."
The Company has not provided a reconciliation of its guidance for adjusted EBITDA to the most directly comparable forward-looking GAAP measures, in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K, because the Company is unable to predict, without unreasonable efforts, the timing and amount of items that would be included in such a reconciliation, including, but not limited to, stock-based compensation expense, and inventory reserve and asset write-offs. These items are uncertain and depend on various factors that are outside of the Company's control or cannot be reasonably predicted. While the Company is unable to address the probable significance of these items, they could have a material impact on GAAP net income and operating expenses for the guidance period.
Forward-looking Statements
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding the potential market opportunities for ZYNRELEF, APONVIE, CINVANTI and SUSTOL; revenue, adjusted EBITDA and other financial guidance provided by the Company; the potential additional market opportunity for the expanded
Heron Therapeutics, Inc. | ||||||||||||||||
Consolidated Statements of Operations | ||||||||||||||||
(Unaudited) | ||||||||||||||||
(In thousands, except per share amounts) | ||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Revenues: | ||||||||||||||||
Net product sales | $ | 37,200 | $ | 36,024 | $ | 76,103 | $ | 70,694 | ||||||||
Cost of product sales | 9,857 | 10,518 | 18,314 | 18,962 | ||||||||||||
Gross profit | 27,343 | 25,506 | 57,789 | 51,732 | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | 2,934 | 4,432 | 5,213 | 9,040 | ||||||||||||
General and administrative | 14,471 | 13,905 | 27,173 | 28,879 | ||||||||||||
Sales and marketing | 11,575 | 13,614 | 23,886 | 25,056 | ||||||||||||
Total operating expenses | 28,980 | 31,951 | 56,272 | 62,975 | ||||||||||||
(Loss) income from operations | (1,637) | (6,445) | 1,517 | (11,243) | ||||||||||||
Other expense, net | (744) | (2,790) | (1,263) | (1,152) | ||||||||||||
Net (loss) income | (2,381) | (9,235) | 254 | (12,395) | ||||||||||||
Other comprehensive loss: | ||||||||||||||||
Unrealized loss on short-term investments | (2) | (2) | (14) | (21) | ||||||||||||
Comprehensive (loss) income | $ | (2,383) | $ | (9,237) | $ | 240 | $ | (12,416) | ||||||||
Basic net (loss) income per share | $ | (0.02) | $ | (0.06) | $ | 0.00 | $ | (0.08) | ||||||||
Diluted net (loss) income per share | $ | (0.02) | $ | (0.06) | $ | 0.00 | $ | (0.08) | ||||||||
Weighted average common shares outstanding, basic | 154,020 | 152,305 | 153,804 | 151,900 | ||||||||||||
Weighted average common shares outstanding, diluted | 154,020 | 152,305 | 197,751 | 151,900 | ||||||||||||
Heron Therapeutics, Inc. | ||||||||
Consolidated Balance Sheets | ||||||||
(in thousands) | ||||||||
June 30, | December 31, | |||||||
(Unaudited) | ||||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 16,516 | $ | 25,802 | ||||
Short-term investments | 24,117 | 33,481 | ||||||
Accounts receivable, net | 79,931 | 78,881 | ||||||
Inventory, net | 72,965 | 53,160 | ||||||
Prepaid expenses and other current assets | 17,394 | 17,690 | ||||||
Total current assets | 210,923 | 209,014 | ||||||
Property and equipment, net | 13,683 | 14,863 | ||||||
Right-of-use lease assets | 1,401 | 2,787 | ||||||
Other assets | 6,083 | 6,483 | ||||||
Total assets | $ | 232,090 | $ | 233,147 | ||||
LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 12,037 | $ | 11,709 | ||||
Accrued clinical and manufacturing liabilities | 17,135 | 25,402 | ||||||
Accrued payroll and employee liabilities | 6,471 | 9,554 | ||||||
Notes payable, net | 25,398 | — | ||||||
Convertible notes payable, net | 149,806 | — | ||||||
Other accrued liabilities | 46,215 | 41,755 | ||||||
Current lease liabilities | 1,539 | 3,037 | ||||||
Total current liabilities | 258,601 | 91,457 | ||||||
Non-current notes payable, net | — | 25,026 | ||||||
Non-current convertible notes payable, net | — | 149,700 | ||||||
Other non-current liabilities | 747 | 615 | ||||||
Total liabilities | 259,348 | 266,798 | ||||||
Stockholders' deficit: | ||||||||
Common stock | 1,533 | 1,521 | ||||||
Additional paid-in capital | 1,890,550 | 1,884,409 | ||||||
Accumulated other comprehensive (loss) income | (1) | 13 | ||||||
Accumulated deficit | (1,919,340) | (1,919,594) | ||||||
Total stockholders' deficit | (27,258) | (33,651) | ||||||
Total liabilities and stockholders' deficit | $ | 232,090 | $ | 233,147 | ||||
Heron Therapeutics, Inc. | ||||||||
Adjusted EBITDA | ||||||||
(Unaudited) | ||||||||
(in thousands) | ||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||
2025 | 2024 | 2025 | 2024 | |||||
Net (loss) income | $ 254 | |||||||
Other expense, net | 744 | 2,790 | 1,263 | 1,152 | ||||
Depreciation | 611 | 641 | 1,162 | 1,330 | ||||
Stock-based compensation | 2,797 | 4,570 | 5,308 | 7,945 | ||||
Adjusted EBITDA | ||||||||
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400
View original content to download multimedia:https://www.prnewswire.com/news-releases/heron-therapeutics-announces-q2-2025-financial-results-and-highlights-commercial-progress-302525114.html
SOURCE Heron Therapeutics, Inc.
FAQ
What were Heron Therapeutics' (HRTX) Q2 2025 earnings results?
How much did Heron Therapeutics reduce its debt in 2025?
What is the growth rate of APONVIE and ZYNRELEF in Q2 2025?
What is Heron's updated 2025 EBITDA guidance?
How much cash does Heron Therapeutics have as of Q2 2025?
